நிறுவப்பட்டது ர்க்ஸ் ப்ராடக்ட்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிறுவப்பட்டது ர்க்ஸ் ப்ராடக்ட்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிறுவப்பட்டது ர்க்ஸ் ப்ராடக்ட்ஸ் Today - Breaking & Trending Today

Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER

Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , France General , Paul Hudson , Regeneron Mabs , Daiichi Sankyo , Biond Biologics , Group Strategy , United State Biomedical Advanced Research , Groupb Vaccine , International Society On Thrombosis , Us District Court , Research Development , Sanofi Business Services , Committee For Orphan Medicinal Products , Industrial Affairs , Development For Dupixent , Sanofi Global Health , European Commission , Drug Administration , World Health Organization , Data Monitoring Committee , Development Authority , Sanofi Global Health Unit , National Reimbursement Drug List , European Medicines Agency ,

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
Specialty Care sales grew 18.3%, driven by strong Dupixent
performance (+54.2% to €982 million).
Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH.
General Medicines declined 7.5%, reflecting lower U.S. Diabetes sales, COVID environment and portfolio streamlining.
CHC down 3.0% due to decreased sales of Cough & Cold related portfolio in Europe partially offset by Digestive Health brands.
Leveraged business EPS as the result of prioritization within R&D and continued execution on smart spending initiatives.
Sales down 2.4% and business EPS flat on a reported basis, as a result of the overall adverse impact from foreign currency rates. ....

United States , United Kingdom , Renagel Renvela , Paul Hudson , Sanofi Regeneron , Synvisc Synvysc , Digestive Health , European Association Of Haemophilia , Sanofi Espoir Foundation , International Society On Thrombosis , Oncology Alliance , Us District Court , Sanofi Business Services , European Union , Animal Health Items , European Commission , Drug Administration , Antibodies Alliance , National Institute For Health , National Reimbursement Drug List , Sanofi Animal Health , Animal Health , European Society For Medical Oncology , Chief Executive Officer , General Medicines , Consumer Healthcare ,